Labcorp to acquire toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients

Burlington, n.c.--(business wire)--labcorp (nyse: lh), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire toxikon, a contract research organization delivering best-in-class nonclinical testing services. once completed, the transaction will create a strategic footprint for labcorp to partner with pharmaceutical and biotechnology clients in the boston, mass., area and bolster its strong nonclinical development portfolio. “adding toxi
LH Ratings Summary
LH Quant Ranking